Your session is about to expire
← Back to Search
Angiotensin Converting Enzyme Inhibitor
Telmisartan for Alzheimer's Disease (SARTAN-AD Trial)
Phase 2
Waitlist Available
Led By Sandra Black, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 & 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing blood pressure medications to see if they can slow brain shrinkage in patients with mild to moderate Alzheimer's Disease. The goal is to find out if these medications can protect the brain and slow down the progression of the disease.
Eligible Conditions
- Alzheimer's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 & 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 & 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety - Adverse Events
Safety - Blood pressure
Safety - Electrolytes
+2 moreSecondary study objectives
Cognitive and functional measures
Grey/White matter volume
Hippocampal volume
Other study objectives
Neuropsychiatric Measures
Quality of Life - Caregiver burden
Quality of Life - Health-related
+2 moreSide effects data
From 2016 Phase 4 trial • 33 Patients • NCT0207980513%
Nasopharyngitis
6%
Abdominal pain lower
6%
Chest discomfort
6%
Bronchitis
6%
Influenza
6%
Diabetes mellitus
6%
Vaginal haemorrhage
6%
Cutaneous amyloidosis
6%
Back pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Telmisartan 40 mg
Azilsartan 20 mg
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TelmisartanExperimental Treatment1 Intervention
Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
Group II: PerindoprilActive Control1 Intervention
Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Telmisartan
1999
Completed Phase 4
~14550
Find a Location
Who is running the clinical trial?
Sunnybrook Health Sciences CentreLead Sponsor
674 Previous Clinical Trials
1,565,705 Total Patients Enrolled
Weston Brain InstituteOTHER
11 Previous Clinical Trials
823 Total Patients Enrolled
Alzheimer's Drug Discovery FoundationOTHER
21 Previous Clinical Trials
2,964 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a type of Alzheimer's disease that runs in families and is inherited from one generation to another.You cannot tolerate or have any medical reasons to avoid taking the study medications.You have experienced angioedema in the past.You are currently taking or have taken a medication called angiotensin receptor blocker within the past year.Your mental state will be assessed using a test, and if your score falls between 16 and 27, you may be excluded from the trial.You have abnormal blood vessels in your brain, regardless of their size or number.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Perindopril
- Group 2: Telmisartan
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger